AbbVie Inc.
Mega Cap · Healthcare · Drug Manufacturers - General
$258.94+$8.61 (+3.44%)
pre-market$256.10▼ -1.09%
AbbVie Inc.
Mega Cap · Healthcare · Drug Manufacturers - General
$258.94+$8.61 (+3.44%)
pre-market$256.10▼ -1.09%
Stock analysis
Get the AI take on ABBV
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$187.62
High$267.47
Today $258.94
RSI (14)
44.8Neutral
03070100
Overall score
59/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$200
Current price
$258.94
Median target
$280
Highest
$328
LowHigh
Operating Record
Revenue
What's working
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
- ROIC: Money put back into the business keeps coming back out as profit, a hallmark of a durable moat.
What to watch
- Debt exceeds cash by $64.3B, increasing balance-sheet pressure, a warning sign.
- Current ratio: Near-term bills are outrunning what's on hand to pay them.
What the market charges
Forward P/E
Favorable · 15% below avg
16.45x
Price / sales
Reasonable · Priced reasonably against its revenue
6.85x
Price / FCF
Reasonable · Priced a bit rich against its cash flow
24.21x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
16.42x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
17.7%
ROE
Favorable · 15221.8% - strong capital efficiency
-
Debt / equity
No signal · Not enough data to judge
-
Current ratio
Weak · Not enough on hand to cover near-term bills
0.81x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $440.83B | 70.5 | +10.4% | 59 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |